 Diffusion Pharmaceuticals Inc NASDAQ: DFFN has announced topline results from the Phase 1 trial of its lead product candidate, trans sodium crocetinate TSC. In the trial, transcutaneous oxygen monitoring TCOM was used to measure the direct pharmacodynamic effects of TSC on peripheral tissue oxygenation in healthy volunteers. 